<DOC>
	<DOCNO>NCT00644618</DOCNO>
	<brief_summary>For patient unresectable locally advanced pancreatic cancer , combine use external-beam radiation therapy ( EBRT ) systemic chemotherapy 5-FU widely recognize effective chemoradiotherapy approach.But patient succumb local recurrence metastasis treatment , prognosis remain poor On basis development superiority interstitial brachytherapy radiosensitizing effect gemcitabine , perform clinical study explore interaction improve I-125 brachytherapy gemcitabine compare regimen standard gemcitabine treatment specifically patient non-metastatic , unresectable pancreatic cancer .</brief_summary>
	<brief_title>Randomized Controlled Trial Gemcitabine Combined With 125I Brachytherapy</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically prove locally advanced pancreatic adenocarcinoma stage No systemic metastasis Age 1875 KarnofskyPerformance Status equal , great 70 % At least 2dimensionally measurable tumor lesion Adequate renal liver function Written consent statement Patients ' compliance geographical proximity Life expectancy equal great 3 month Serious psychological disease Pregnancy inadequate secure contraception breastfeed woman Other previous malignant disease past two year Serious systemic concomitant disease , exclude participation trial Other experimental treatment within 6 week prior trial ( include chemotherapeutic medicine immunetherapies ) Every condition therapy assess physician eventual risk patient restrict aim trial Distant metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>locally advanced</keyword>
</DOC>